Novel Approaches to Neurodegenerative Disorders

2.1 The Impact of Neurodegenerative Diseases

• Cost to Society
• Impact on Society

2.2 The Evolving Disease Demographics of an Aging Population

• Changing Disease Demographics
• Better and Earlier Disease Diagnosis

2.3 Unmet Medical Needs
2.4 Conceptual Breakthroughs in the Understanding of Neurodegenerative Diseases
2.5 Common Pathways and Technologies Across a Broad Spectrum of Diseases
2.6 The Impact of Improved Diagnostics
2.7 Identification of Neurological Disease Targets through Genomics
2.8 The Ideal Therapy

3. Technology Review and Assessment

3.1 New Disease Models

• Oxidative Theory
• Mitochondrial Model
• Apoptosis Theory
• Vascular Theory
• Toxic Protein Theory
• Immune and Inflammation Theory
• The Role of Metals
• Excitoxicity and NMDA Receptors

3.2 New Targets and the Generation of Lead Compounds

3.3 The Blood Brain Barrier

• The Function of the BBB
• Limitations on Drug Discovery and Lead Selection
• In Vitro Assays
• Chemical Informatic Approaches
• Predicting BBB
• BBB Permeability of Novel Compounds
• Increasing BBB Permeability
• Pumps, Microinjection and Other Mechanical Means

3.4 Combinatorial Chemistry and High Throughput Screening Assays

3.5 In Vivo and In Vitro Models as Tools in Neurological Research

• Cybrids
• Transgenic Animal Models
• Cell-based Systems
• In Vivo Imaging Systems

3.6 Gene Therapy
3.7 Cellular Therapy (Encapsulated and Non- Encapsulated)
3.8 Neuropharmacogenomics
3.9 Surgical Models for Therapy

3.10 Alternative Treatments

• Phytoceuticals
• Nutraceuticals
• Virtual Reality-Based Therapy
• Traditional Chinese Approaches

3.11 Diagnostics and Monitoring for Diagnostics

• Blood Tests
• Platelet Assays
• CSF Fluids
• Improved Brain Imaging Methods for Real Time Tracking of Drug Activity

4. Clinical Applications and Medical Practice Trends

4.1 Current Trends in Diagnosis and Treatment

• ALS
• Alzheimer's Disease
• Huntington's Disease
• Parkinson's Disease
• Stroke
• Trauma

4.2 Common Pathways-Common Treatments
4.3 Limitations in Clinical Research
4.4 Evaluation of Therapeutic Strategies and Drug Classes in Development
4.5 Forecasts of Future Therapeutic Trends

5. Market Analysis

5.1 Major Stakeholders and Their Influence

• Pharmaceutical Companies
• Biotechnology Companies
• Consumers and Suppliers
• AARP
• Long-Term Care Organizations
• Managed Care Organizations
• Third Party Medical Associations
• Physicians and Elderly-Geriatric Specialists
• University Research Institutions

5.2 Regulatory Issues (FDA)

5.3 Market Segmentation by Disease Groups

• Disease Frequency
• Cost to Society
• Cost of Treatment (Current and Emerging)
• Competitive Environment

5.4 The Impact of Diagnostics in Expanding Market Size

• Advances in Early Detection
• Genetic Screening

5.5 Impact and Economics of Neuropharmacogenomics

• The ApoE Alzheimer's Story
• Current Efforts in SNP'ing Neurological Diseases

5.6 Barriers to Implementation of Specific Therapies and Diagnostics

• Fetal Cell Implants
• Gene Therapy
• Genetic Testing
• Pharmacogenomic Profiling
• Competitive Pressures from Alternative Medical
• Treatments and Procedures
• Nutraceuticals and Phytoceuticals
• Surgical Procedures and Medical Devices

5.7 Commercialization Strategies
5.8 Market Forecasts

6. Company Profiles

• Small Companies Dedicated to Neurological Drug Development
• Large Companies with Dedicated Neurological Drug Development
• Companies Developing Neurological Gene Therapy, Cell Therapy, etc.
• Neurological Imaging Device Companies

7. Indices

• Bibliography
• Web links
• Product Index